Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the impact of pre-operative cryoablation,
ipilimumab and nivolumab on on 3-year Event Free Survival (EFS), in women with residual
hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after
taxane-based neoadjuvant chemotherapy.